EyePoint, Inc. Third Consecutive Positive DSMC in Hand; Eyes Next on LUGANO Mid-2026

Research evidence excerpt

EyePoint, Inc. Third Consecutive Positive DSMC in Hand; Eyes Next on LUGANO Mid-2026

J P M O R G A N North America Equity Research

22 May 2026

EyePoint, Inc. Overweight

EYPT, EYPT US

Third Consecutive Positive DSMC in Hand; Eyes Next Price (21 May 26):$12.78

on LUGANO Mid-2026 Price Target (Dec-26):$33.00

SMid Biotechnology

Tessa T Romero AC

(1-212) 622-4484

tessa.t.romero@jpmchase.com

Caroline Pocher

EyePoint continues to execute across its pipeline towards key milestones and remains (1-212) 622-8204

caroline.pocher@jpmchase.com

on track to report topline 56wk data from the phase 3 LUGANO trial in mid-2026 and

Mariam Waggehthe phase 3 LUCIA trial shortly thereafter; recall, both trials are evaluating Duravyu

(1-212) 622-1711

(2.7mg) compared with on-label 2mg aflibercept in wet age-related macular mariam.waggeh@jpmchase.com

degeneration (wet AMD; >900 patients enrolled. Last week, EyePoint announced that J.P. Morgan Securities LLC

the independent Data Safety Monitoring Committee (DSMC) completed its third

scheduled review of the phase 3 program for wet AMD and recommended that both

the LUGANO and LUCIA trials continue as planned with no protocol Key Changes (FYE Dec)

modifications. We note that as of May 2, 2026, all active patients in the treatment arm Prev Cur Δ

Adj. EPS - 26E ($) (3.18) (3.25) -2.5%

have reached the Week 32 visit, during which patients received their second Duravyu Adj. EPS - 27E ($) (0.98) (0.83) 15.0%

dose. Of these patients, over 35% have also received their third planned dose at Week

56. Additionally, interim masked safety data from the phase 3 trials show a continued Quarterly Forecasts (FYE Dec)

favorable safety profile for Duravyu, consistent with the safety observed in >190 Adj. EPS ($)

patients across its four completed clinical trials.